UnknownPhase 1/2

Minocycline Treatment for Cystoid Macular Edema

China5 participantsStarted 2019-01-01

Plain-language summary

Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant diagnosed with CME. * Participant aged from 18-60 years old. * Participant that signed the informed consent document and is able to complete the following visits. Exclusion Criteria: * Participant is allergy to minocycline or tetracyclines. * Participant has no contraindications of minocycline or tetracyclines. * Participant has an abnormal function of liver, heart, kidney and thyroid. * Female that is pregnant, breast-feeding or planning to become pregnant. * Participant that is currently using other medications.

What they're measuring

Change of cystoid macular edema

Timeframe: At 6 months

Trial details

NCT IDNCT05474950

SponsorSun Yat-sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-01

View on ClinicalTrials.gov More Minocycline trials